Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Shuangyue Pan"'
Autor:
Mengdi Yang, Jianing Cao, Tiantian Liu, Bin Li, Jinyan Wang, Shuangyue Pan, Duancheng Guo, Zhonghua Tao, Xichun Hu
Publikováno v:
Clinical and Translational Medicine, Vol 14, Iss 11, Pp n/a-n/a (2024)
Abstract Background Triple‐negative breast cancer (TNBC) is distinguished by a significant likelihood of distant recurrence and an unfavourable prognosis. However, the underlying molecules and mechanisms have not been fully elucidated. Methods We i
Externí odkaz:
https://doaj.org/article/9e2acecfa8964c78b3be8b52b30d265d
Autor:
Xiaochen Chen, Huafeng Qiu, Yunwang Chen, Mingxing Wang, Pengfei Zhu, Shuangyue Pan, Yaya Deng, Liu Yang, Zheling Chen
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundsAs a new oral chemotherapy drug, TAS-102 is currently recommended as the third-line treatment for metastatic colorectal cancer (mCRC). Recently, studies have reported the efficacy of TAS-102 combined with bevacizumab in colon cancer patien
Externí odkaz:
https://doaj.org/article/5a76542d8711429db90335abfcc39a75
Publikováno v:
Frontiers in Molecular Biosciences, Vol 8 (2021)
Coronavirus disease-2019 (COVID-19) has spread rapidly around the world and has become a public health emergency of international concern. The weekly epidemiological report issued by the WHO pointed out that new coronavirus variants have appeared in
Externí odkaz:
https://doaj.org/article/4b46e66c649d4e0ab30691be0cb562e4
Autor:
Yaya Deng, Dingyi Jiang, Peng-Fei Zhu, Hongrui Lu, Qian Liu, Xinyue Zhang, Shuangyue Pan, Zhe-Ling Chen, Liu Yang
Publikováno v:
World Journal of Surgical Oncology. 21
Background Recently, many studies have shown that the progress of conversion therapy can provide surgical opportunities for patients with advanced gastric cancer (GC) and bring survival benefits. However, the results of the current study show that th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f97743096593dc340e31f55bc06a6304
https://doi.org/10.1186/s12957-023-02973-3
https://doi.org/10.1186/s12957-023-02973-3
Publikováno v:
Anti-Cancer Drugs
Pancreatic cancer is digestive cancer with limited therapeutic options and a poor outcome. Pancreatic cancer has a high mortality rate, with a 5-year survival rate of less than 5%. The median survival after metastasis of the disease is less than 6 mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80963be43877c530690a97d9623e356a
http://europepmc.org/articles/PMC8670360
http://europepmc.org/articles/PMC8670360